23andMe Holding Co (ME) - Gross Profit Rate

ME (23andMe Holding Co) - company brandmark

A unique array of genetic data forms a powerful defensive barrier for 23andMe Holding Co. (ME). The company generates revenue through the sale of DNA tests and partnerships with pharmaceutical behemoths. The gross margin as a percentage of revenue clearly demonstrates profitability, where 40.60 determines the current value of this metric. The integration of consumer data into scientific research transforms the business into a central hub for modern personalized medicine.

ME (23andMe Inc.) Gross Profitability history from 07/04/2022 to 04/05/2025

Financial and market metric breakdowns for 23andMe (ME)

- stock value and consensus price forecast:
- market capitalization indicators:
Fundamental valuation:ME - 23andMe Holding Co
Finished products of 23andme.com

To minimize long-term risks, it is crucial for investors to monitor production efficiency and the cost of capital. In the case of 23andMe Holding Co. (ME), operating profitability depends on the synergy between genetic databases and partnerships with pharma behemoths in the development of targeted drugs. By analyzing the gross margin percentage, you can see the portion of revenue minus direct costs, which determines the business's resilience to external shocks and the level of WACC.